PR Newswire·Oct 21, 2026, 7:30 AM ET

Keenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026

Keenova Therapeutics will present two studies on HRS-AKI and TERLIVAZ (terlipressin) at the American Society of Nephrology Kidney Week 2026 in Dublin.
TERLIVAZ is the first & only FDA-approved therapy for improving kidney function in adults with HRS-AKI.
A retrospective cohort study evaluating real-world outcomes in U.S. adults will be presented as a poster on October 22.
An exploratory subgroup analysis of the CONFIRM trial regarding renal replacement therapy in transplant-ineligible patients will be presented as an oral abstract on October 24.
HRS-AKI is a life-threatening condition marked by rapid kidney function decline in adults with advanced liver disease.
U.S. hospitalizations for HRS increased from 42,930 in 2018 to 63,381 in 2023.
TERLIVAZ is not indicated for patients with serum creatinine levels greater than 5 mg/dL.
The drug carries a boxed warning for serious or fatal respiratory failure, particularly in patients with volume overload or ACLF Grade 3.
TERLIVAZ is contraindicated for patients with hypoxia, worsening respiratory symptoms, or ongoing ischemia.
Common adverse reactions (occurring in ≥10% of patients) include abdominal pain, nausea, respiratory failure, diarrhea, & dyspnea.
Keenova Therapeutics is headquartered in Dublin, Ireland, with U.S. manufacturing facilities in Louisiana, New Jersey, New York, Pennsylvania, & Wisconsin.